Cargando…

Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant

STUDY OBJECTIVES: Recent treatment guidelines for chronic insomnia recommend pharmacological and non-pharmacological therapies. One of the contemporary drug options for insomnia includes dual orexin receptor antagonist (DORA), such as suvorexant and lemborexant. We conducted a systematic review and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khazaie, Habibolah, Sadeghi, Masoud, Khazaie, Sepideh, Hirshkowitz, Max, Sharafkhaneh, Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792135/ https://www.ncbi.nlm.nih.gov/pubmed/36578296 http://dx.doi.org/10.3389/fpsyt.2022.1070522

Ejemplares similares

Suvorexant: The first orexin receptor antagonist to treat insomnia
por: Dubey, Ashok K., et al.
Publicado: (2015)

Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users
por: Landry, Ishani, et al.
Publicado: (2022)

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant
por: Norman, Jessica L, et al.
Publicado: (2016)

Lemborexant for insomnia
Publicado: (2021)

Alterations of Subcortical Brain Structures in Paradoxical and Psychophysiological Insomnia Disorder
por: Emamian, Farnoosh, et al.
Publicado: (2021)

The effect of lemborexant for insomnia disorder
por: Suzuki, Hidenobu, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
por: Lalovic, Bojan, et al.
Publicado: (2020)

The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act
por: Moline, Margaret, et al.
Publicado: (2023)

Profile of suvorexant in the management of insomnia
por: Sutton, Eliza L
Publicado: (2015)

Alpha-wave Characteristics in Psychophysiological Insomnia
por: Rezaei, Mohammad, et al.
Publicado: (2019)

Suvorexant, a Dual Orexin Receptor Antagonist, Protected Seizure through Interaction with GABA(A) and Glutamate Receptors
por: Razavi, Bibi Marjan, et al.
Publicado: (2020)

Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
por: Beuckmann, Carsten Theodor, et al.
Publicado: (2019)

Psychometric properties of insomnia severity index in Iranian adolescents
por: Chehri, Azita, et al.
Publicado: (2021)

Serum testosterone/cortisol ratio in people with obstructive sleep apnea
por: Mohammadi, Hiwa, et al.
Publicado: (2019)

Hypothalamic–Pituitary–Gonadal Activity in Paradoxical and Psychophysiological Insomnia
por: Mohammadi, Hiwa, et al.
Publicado: (2019)

Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats
por: Illenberger, Jessica M., et al.
Publicado: (2023)

Orexin receptor antagonists as therapeutic agents for insomnia
por: Equihua, Ana C., et al.
Publicado: (2013)

Suvorexant: a promising, novel treatment for insomnia
por: Lee-Iannotti, Joyce K, et al.
Publicado: (2016)

2420 Examining characteristics of placebo effects on trauma-related insomnia in a suvorexant trial
por: Uweh, Kimberly
Publicado: (2018)

EEG/EOG/EMG data from a cross sectional study on psychophysiological insomnia and normal sleep subjects
por: Rezaei, Mohammad, et al.
Publicado: (2017)

Pilot Study of Lemborexant for Insomnia in Cancer Patients with Delirium
por: Terada, Tatsuto, et al.
Publicado: (2022)

Efficacy and safety of lemborexant in midlife women with insomnia disorder
por: Terauchi, Masakazu, et al.
Publicado: (2023)

Personality proﬁles in paradoxical insomnia: a case-control study
por: Rezaie, Leeba, et al.
Publicado: (2020)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
por: Kishi, Taro, et al.
Publicado: (2015)

Suvorexant for insomnia in older adults: a perspective review
por: Tampi, Rajesh R, et al.
Publicado: (2018)

Treatment of chronic insomnia with atypical antipsychotics: results from a follow-up study
por: Khaledi-Paveh, Behnam, et al.
Publicado: (2021)

Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis
por: McElroy, Heather, et al.
Publicado: (2021)

PTSD-related paradoxical insomnia: an actigraphic study among veterans with chronic PTSD
por: Ghadami, Mohammad Rasoul, et al.
Publicado: (2015)

The Comparison of Emotional Dysregulation and Experiential Avoidance in Patients with Insomnia and Non-Clinical Population
por: Zakiei, Ali, et al.
Publicado: (2020)

The effect of acceptance and commitment therapy on insomnia and sleep quality: A systematic review
por: Salari, Nader, et al.
Publicado: (2020)

Partitioning the Sleep Quality and Insomnia Severity among Earthquake Victims in the West of Iran: Cluster Prediction Based on Personality and Psychological Factors
por: Khazaie, Habibolah, et al.
Publicado: (2019)

Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
por: Landry, Ishani, et al.
Publicado: (2020)

Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study
por: Mayleben, David, et al.
Publicado: (2021)

Respiration data on sleep state misperception, psychophysiological insomnia and normal individuals from a cross sectional study
por: Rezaei, Mohammad, et al.
Publicado: (2019)

Weight and metabolic effects of cpap in obstructive sleep apnea patients with obesity
por: Garcia, Jose M, et al.
Publicado: (2011)

When Non-Suicidal Self-Injury Predicts Non-Suicidal Self-Injury and Poor Sleep—Results from a Larger Cross-Sectional and Quasi-Longitudinal Study
por: Khazaie, Habibolah, et al.
Publicado: (2021)

Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
por: Uchiyama, Makoto, et al.
Publicado: (2022)

PSUN201 Efficacy and Safety of Lemborexant in Diabetic Patients With Insomnia Disorder
por: Moline, Margaret, et al.
Publicado: (2022)

Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
por: Roch, Catherine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_phb4uv88sos1kqrnl8umbkb47r